Name: Living with Narcolepsy: Saturday Support Group
Start: 2025-01-04T13:30:00-05:00
End: 2025-01-04T14:30:00-05:00
Location: HeyPeers Website

May 02 2023
Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy

Posted at May 02 2023
h in News by Cara Weaver

Avadel Pharmaceuticals May 1 2023 PDF

https://investors.avadel.com/news-releases/news-release-details/avadel-pharmaceuticals-announces-final-fda-approval-lumryztm

Print page

May 02 2023 Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy

2 events, 25

2 events, 25

1 event, 26

1 event, 26

2 events, 27

2 events, 27

1 event, 28

1 event, 28

1 event, 29

1 event, 29

1 event, 30

1 event, 30

0 events, 1

0 events, 1

2 events, 2

2 events, 2

2 events, 3

2 events, 3

GivingTuesday 2024

GivingTuesday 2024

2 events, 4

2 events, 4

2 events, 5

2 events, 5

1 event, 6

1 event, 6

1 event, 7

1 event, 7

0 events, 8

0 events, 8

2 events, 9

2 events, 9

1 event, 10

1 event, 10

2 events, 11

2 events, 11

2 events, 12

2 events, 12

1 event, 13

1 event, 13

1 event, 14

1 event, 14

0 events, 15

0 events, 15

2 events, 16

2 events, 16

1 event, 17

1 event, 17

2 events, 18

2 events, 18

1 event, 19

1 event, 19

1 event, 20

1 event, 20

1 event, 21

1 event, 21

0 events, 22

0 events, 22

2 events, 23

2 events, 23

May 02 2023
Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy